喘中的疾病修饰:我们在正确的道路上吗? 一个多学科专家德尔菲共识 (MODIASTHMA共识)
Juan Carlos Miralles-López1,2, Francisco J Alvarez-Gutiérrez3, Julio Delgado-Romero4
1Allergy Department, University General Hospital Reina Sofia, Murcia, Spain.
Journal of asthma and allergy
|November 19, 2024
概括
专家们就修改严重喘的关键方面达成共识,重点关注临床,功能和病理生理因素. 这一协议对于推进喘管理策略和开发新的治疗目标至关重要.
科学领域:
- 肺部病理学 肺部病理学
- 过敏学 过敏学
- 儿科 儿科 儿科
背景情况:
- 新兴的生物疗法促使新的喘管理目标,包括疾病修饰.
- 在喘中定义"疾病修饰"需要科学共识.
- 目前的定义缺乏标准化,阻碍了治疗的进步.
研究的目的:
- 在喘管理中制定疾病修饰的商定定义.
- 确定实现喘疾病修饰的基本标准和指标.
- 促进针对严重喘的新型治疗策略的开发.
主要方法:
- 一个多学科专家小组 (192名专家) 被召集.
- 一个系统的文献审查告知了陈述开发.
- 通过使用9点利克特级别的德尔菲方法,对疾病修饰标准的22个陈述进行了评估.
主要成果:
- 在第一轮中,所有22个陈述都达到了高度共识 (中位数>7).
- 肺病学家,过敏学家和儿科医生一致同意了基本的标准.
- 该研究成功地确定了疾病修饰的关键临床功能和病理生理方面.
结论:
- 这项德尔菲研究建立了专家的共识,定义了喘中的疾病修饰.
- 在关键的临床,功能和病理生理学方面达成协议.
- 这些发现为推进喘管理和治疗开发提供了基础.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-IV: Nursing Management
3.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.0K
COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Antiasthma Drugs: Leukotriene Modifiers
245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
245
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237


